BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21620302)

  • 1. [Variation of urinary PCA3 following transrectal ultrasound-guided prostate biopsy].
    Prezelin Y; Ronsin C; Celhay O; Pirès C; Doré B; Fromont G; Larré S; Irani J
    Prog Urol; 2011 Jun; 21(6):412-6. PubMed ID: 21620302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score.
    De Luca S; Passera R; Milillo A; Coda R; Randone DF
    BJU Int; 2012 Dec; 110(11 Pt B):E778-82. PubMed ID: 23116408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
    Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
    Pepe P; Aragona F
    Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
    Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study.
    Galasso F; Giannella R; Bruni P; Giulivo R; Barbini VR; Disanto V; Leonardi R; Pansadoro V; Sepe G
    Arch Ital Urol Androl; 2010 Mar; 82(1):5-9. PubMed ID: 20593708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
    Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in ∼2000 patients.
    Brown JG; Fulmer JR; Romano J; Pownell J; Rigler W; Wirtshafter A; Sarno M; Shappell SB
    Urology; 2014 Nov; 84(5):1172-80. PubMed ID: 25443926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate.
    Henderson J; Ghani KR; Cook J; Fahey M; Schalken J; Thilagarajah R
    J Endourol; 2010 Nov; 24(11):1821-4. PubMed ID: 20964483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.
    Panebianco V; Sciarra A; De Berardinis E; Busetto GM; Lisi D; Buonocore V; Gentile V; Di Silverio F; Passariello R
    Anticancer Res; 2011 Apr; 31(4):1399-405. PubMed ID: 21508392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.
    Okcelik S; Soydan H; Ates F; Berber U; Saygin H; Sonmez G; Karademir K
    Int Braz J Urol; 2016; 42(3):449-55. PubMed ID: 27286106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
    BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological patterns of prostate biopsy in men with fluctuations of prostate cancer gene 3 score: a preliminary report.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Porpiglia F
    Anticancer Res; 2015 Apr; 35(4):2417-22. PubMed ID: 25862908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies.
    Borboroglu PG; Comer SW; Riffenburgh RH; Amling CL
    J Urol; 2000 Jan; 163(1):158-62. PubMed ID: 10604336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.